BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Summary by AI BETAClose X

BioNTech reported first quarter 2026 revenues of €118.1 million, with a net loss of €531.9 million (€2.10 diluted loss per share), and reaffirmed its full-year 2026 guidance of €2,000 – €2,300 million in revenues. The company is advancing its oncology pipeline with multiple pivotal trials initiated for pumitamig and expects six late-stage pipeline data readouts this year. BioNTech also announced plans to consolidate its manufacturing footprint, aiming for approximately €500 million in annual savings by 2029, and intends to launch a share repurchase program of up to $1.0 billion. The company maintains a strong financial position with €16.8 billion in cash, cash equivalents, and security investments.

Disclaimer*

UK 100

Latest directors dealings